Home
Per Omvik's picture

Per Omvik

Professor
  • E-mailPer.Omvik@uib.no
  • Phone+47 55 97 30 30+47 951 58 728
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2012). Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: A LIFE study. American Journal of Hypertension. 1017-1023.
  • Show author(s) (2011). Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy. Journal of Hypertension. 997-1004.
  • Show author(s) (2009). Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: The Losartan Intervention For End point reduction in hypertension (LIFE) study. American Heart Journal. 177-184.
  • Show author(s) (2009). Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. Blood Pressure. 348-361.
  • Show author(s) (2009). Left ventricular long-axis function in treated haemochromatosis. The International Journal of Cardiac Imaging. 237-247.
  • Show author(s) (2009). Left ventricular diastolic function in patients with treated haemochromatosis. Scandinavian Cardiovascular Journal. 32-38.
  • Show author(s) (2009). Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study. NMCD. Nutrition Metabolism and Cardiovascular Diseases. 306-312.
  • Show author(s) (2009). Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan intervention For Endpoint reduction in hypertension study. Journal of Hypertension. 567-574.
  • Show author(s) (2009). Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. Journal of Hypertension. 567-574.
  • Show author(s) (2008). Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. American Heart Journal. 177-184.
  • Show author(s) (2008). Losartan compared with atenolol has positive effects on lipid metabolism in patients with hypertension and left ventricular hypertrophy: The LIFE Study. Journal of Hypertension.
  • Show author(s) (2007). Reduced exercise capacity in genetic haemochromatosis. European Journal of Cardiovascular Prevention & Rehabilitation. 470-475.
  • Show author(s) (2007). Left atrial size and risk of major cardiovascular events during antihypertensive treatment - Losartan intervention for endpoint reduction in hypertension trial. Hypertension. 311-316.
  • Show author(s) (2006). Exercise performance during losartan- or atenolol-based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). Blood Pressure. 220-226.
  • Show author(s) (2005). The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. The Journal of Clinical Hypertension. 152-158.
  • Show author(s) (2005). The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. Journal of Hypertension. 152-158.
  • Show author(s) (2005). The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. Journal of the American College of Cardiology. 770-775.
  • Show author(s) (2005). Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension. 46-52.
  • Show author(s) (2005). Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 198-202.
  • Show author(s) (2005). Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Hypertension. 580-585.
  • Show author(s) (2005). Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. Circulation. 1924-1931.
  • Show author(s) (2004). The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney International. 1014-1049.
  • Show author(s) (2004). Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: The LIFE study. Blood Pressure. 376-384.
  • Show author(s) (2004). Hypertensjon og hjertesykdom. Tidsskrift for Den norske legeforening. 802-805.
  • Show author(s) (2004). Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. Journal of Hypertension. 1805-1811.
  • Show author(s) (2004). Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. Journal of Hypertension. 1805-1811.
  • Show author(s) (2004). Blood pressure measurements by the Keito machine. Evaluation versus office blood pressure by physicians. Blood Pressure Monitoring. 167-172.
  • Show author(s) (2004). Behandling av høyt blodtrykk hos pasienter med venstre<BR/>ventrikkel-hypertrofi. Tidsskrift for Den norske legeforening. 788-791.
  • Show author(s) (2004). Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study. Journal of Human Hypertension. 381-389.
  • Show author(s) (2003). The Norwegian office-, home-, and ambulatory blood pressure study (NOHA). Blood Pressure. 211-219.
  • Show author(s) (2003). Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Annals of Internal Medicine. 169-177.
  • Show author(s) (2003). Allergi, astma og livsstil - epidemiologisk grunnlag - utbredelse. Fagbladet Allergi i praksis. 7-9.
  • Show author(s) (2003). Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Annals of Internal Medicine. 901-906.
  • Show author(s) (2002). Twenty-four-hour ambulatory blood pressure monitoring in atrial fibrillation. Blood Pressure Monitoring. 149-156.
  • Show author(s) (2002). Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. Journal of Hypertension. 1879-1886.
  • Show author(s) (2002). Impact of diastolic Doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). Journal of Hypertension. 1223-1229.
  • Show author(s) (2002). Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. Journal of the American Medical Association (JAMA). 1491-1498.
  • Show author(s) (2002). Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet. 995-1003.
  • Show author(s) (2002). Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet. 1004-1010.
  • Show author(s) (2001). Renal hemodynamic effects of captopril and doxazosin during slight physical activity in hypertensive patients with type-1 diabetes mellitus. Kidney and Blood Pressure Research. 64-70.
  • Show author(s) (2001). A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension. Managed Care Interface. 82-87.
  • Show author(s) (2000). Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy. The LIFE study. American Journal of Hypertension. 899-906.
  • Show author(s) (2000). Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy. The LIFE study. American Journal of Hypertension. 899-906.
  • Show author(s) (2000). Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension. American Heart Journal. 624-630.
  • Show author(s) (2000). Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension. American Heart Journal. 624-630.
  • Show author(s) (2000). Cardiac biochemical markers after cardioversion of atrial fibrillation or atrial flutter. American Heart Journal. 690-694.
  • Show author(s) (2000). Cardiac biochemical markers after cardioversion of atrial fibrillation or atrial flutter. American Heart Journal. 690-694.
  • Show author(s) (1999). Similar central hemodynamics in salt sensitive and salt resistant hypertensive patients. Blood Pressure. 233-241.
  • Show author(s) (1999). Similar central hemodynamics in salt sensitive and salt resistant hypertensive patients. Blood Pressure. 233-241.
  • Show author(s) (1999). Reproducibility of salt sensitivity testing using a dictary approach in essential hypertension. Journal of Human Hypertension. 375-384.
  • Show author(s) (1999). Cardiac biochemical markers after cardioversion of atrial fibrillation. Scandinavian Cardiovascular Journal. 24.
  • Show author(s) (1998). Årsaker til og konsekvenser av mild hypertensjon? Tidsskrift for Den norske legeforening. 4396-4398.
  • Show author(s) (1998). The Bergen Blood pressure Study: changes in cardiac structure and function in offspring of hypertensive families. European Heart Journal. 474-474.
  • Show author(s) (1998). Konsensus om hypertensjon? Tidsskrift for Den norske legeforening. 3979-3981.
  • Show author(s) (1998). Is salt sensitivity a temporary phenomenon? Journal of Hypertension. 150-150.
  • Show author(s) (1998). Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using captopril or doxazosin for months months. American Journal of Hypertension. 1178-1187.
  • Show author(s) (1998). Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using Captopril or Doxazosin for months. American Journal of Hypertension. 1178-1187.
  • Show author(s) (1998). Factors Influencing Left Ventricular Mass in Salt Sensitive and Salt Resistant Essential Hypertensive Patients. Blood Pressure. 223-230.
  • Show author(s) (1998). Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE study. Hypertension. 989-997.
  • Show author(s) (1998). Beta-2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study. Kidney International. 1455-1460.
  • Show author(s) (1997). Regression of left ventricular hypertrophy in type-1 diabetic patients using doxazosin as antihypertensive therapy @<abstract@>. Journal of Hypertension. 40.
  • Show author(s) (1997). Factors influencing LVM in hypertensitive type-1 diabetic patients. Blood Pressure. 197-202.
  • Show author(s) (1997). Factors influencing LVM in hypertensitive type-1 diabetic patients. Blood Pressure. 197-202.
  • Show author(s) (1997). Angiotensin converting enzyme inhibition and alpha<SUB>1</SUB>-receptor blockade as antihypertensive therapy in type-1 diabetic patients. American Journal of Hypertension. 121A.
  • Show author(s) (1996). Factors influencing left ventricular mass in hypertensive type-1 diabetic patients. American Journal of Hypertension. 65A.
Report
  • Show author(s) (2000). Hjerteinfarkt (revidert utgave). .
Academic lecture
  • Show author(s) (2003). Left atrial size and risk of major cardiovascular events in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE trial).
  • Show author(s) (2002). The impact of concomitant diabtes on changes in left ventricular structure and function during antihypertensive treatment (the LIFE study).
  • Show author(s) (2000). The effect of losartan treatment on left ventricular hypertrophy in patients with essential hypertension.
  • Show author(s) (2000). The effect of losartan treatment on left ventricular hypertrophy in patients with essential hypertension.
  • Show author(s) (2000). Reduction in left ventricular mass and blood pressure is not accompanied by improved exercise performance in hypertensive patients with left ventricular hypertrophy.
  • Show author(s) (2000). Reduction in left ventricular mass and blood pressure is not accompanied by improved exercise performance in hypertensive patients with left ventricular hypertrophy.
  • Show author(s) (1999). Troponin I and T in atrial fibrillation.
  • Show author(s) (1999). Cardiac biochemical markers after cardioversion of atrial fibrillation.
  • Show author(s) (1997). The alerting reaction to conventional blood pressure measurement is more pronounced in offspring of hypertensive than normotensive parents.
  • Show author(s) (1997). Increased alerting reaction to conventional blood pressure measurement in offspring of hypertensive parents.
Non-fiction book
  • Show author(s) (2000). Hjerteinfarkt (revidert utgave). Nasjonalforeningen. Det norske råd for hjerte og karsykdommer.
Feature article
  • Show author(s) (2004). Hvorfor ikke alltid diuretika? Tidsskrift for Den norske legeforening. 1419-1420.
  • Show author(s) (1999). Helsefare på Haukeland sykehus. Bergens Tidende.
  • Show author(s) (1998). Will the millimetre of mercury be replaced by the kilopascal? Journal of Hypertension. 1055-1056.
Academic chapter/article/Conference paper
  • Show author(s) (2014). Hemodynamics and Hypertension. 14 pages.
  • Show author(s) (2000). Pågående multisenterstudier i hypertensjon - faglig medisinsk betydning og konsekvenser for pasienten. 4 pages.
Abstract
  • Show author(s) (2005). Influence of hypertension on angiographic findings in patients with angina pectoris. American Journal of Hypertension. 175A.
  • Show author(s) (2004). Blood pressure and cardiovascular risk factors in hypertensive patients referred to a regional hospital in Ghana. American Journal of Hypertension. A196.
Poster
  • Show author(s) (2003). Comparison of blood pressure measurements by the Keito machine to casual blood pressure measured by physicians.
  • Show author(s) (1999). Factors influencing cardiac hypertrophy in type-1 diabetes mellitus.
Academic literature review
  • Show author(s) (2009). Central haemodynamics of hypertension. Archives of Medical Science. 220-228.

More information in national current research information system (CRIStin)